

## Aspira Women's Health to Participate at the Upcoming MicroCap Rodeo Windy City Roundup 2022

### Description

October 06, 2022 16:05 ET

AUSTIN, Texas, Oct. 06, 2022 (GLOBE NEWSWIRE) — Aspira Women's Health, Inc. (Nasdaq: AWH), a bioanalytical-based women's health company, today announced that management will present and be available for 1x1 meetings at the MicroCap Rodeo Presents Windy City Roundup 2022 conference taking place in-person on October 12-13, 2022 in Chicago, IL. Details for the event are below:

#### **Microcap Rodeo Presents Windy City Roundup 2022**

Date: Wednesday, October 12, 2022  
Time: 9:30 am Central Time / 10:30 am Eastern Time

Webcast: [click HERE](#)

To receive additional information, request an invitation or to schedule a 1x1 meeting, please email [angie.goertz@issuereirect.com](mailto:angie.goertz@issuereirect.com). Investors may also register for the event [HERE](#).

A link to the live event also will be available on the [Events & Presentation](#) page of the Aspira Women's Health Investor Relations website.

#### **About Aspira Women's Health Inc.**

Aspira Women's Health Inc.<sup>SM</sup> is transforming women's health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management, and improve gynecologic health outcomes for women. Aspira Women's Health is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis. OVA1plus<sup>®</sup> combines our FDA-cleared products, OVA1<sup>®</sup> and OVERA<sup>®</sup>, to detect risk of ovarian malignancy in women with adnexal masses. Aspira GenetiX<sup>™</sup> testing offers both targeted and comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment, Aspira Women's Health is working to deliver a portfolio of pelvic mass products over a patient's lifetime with our cutting-edge research. The next generation of products in development include OVAWatch<sup>™</sup> and EndoCheck<sup>™</sup>. To improve patient accessibility, Aspira Women's Health has launched our Aspira Synergy<sup>SM</sup> technology transfer platform to empower health systems, academics, regional labs, and physician group labs to conduct genetic and specialty tests in-house. Visit our website for more information at [www.aspirawh.com](http://www.aspirawh.com).

#### **Investor Relations Contact:**

Ashley R. Robinson  
LifeSci Advisors, LLC  
Tel: 617-430-7577  
[Arr@lifesciadvisors.com](mailto:Arr@lifesciadvisors.com)